Evolva und Roche beginnen Forschungszusammenarbeit

04.01.2010 | von Evolva AG

04.01.2010, Evolva Holding AG (SIX: EVE) gab heute die Unterzeichnung einer Vereinbarung mit Roche (SIX: ROG, RO; OTCQX: RHHBY) bekannt, in deren Rahmen die beiden Unternehmen über die Technologieplattform von Evolva zielgerichtete Wirkstoffe für onkologische Erkrankungen und Infektionskrankheiten entwickeln wollen.

Über Evolva AG:

We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world.

The Company’s primary corporate goal is to build a profitable and sustainable business around its core competencies in compound and pathway discovery and development, and from the commercialisation (by Evolva or its partners) of its product candidates.

We aim to “embed” the results of our technology in products or processes that are partnered with companies and organisations with the expertise and resources to commercialise the products.

Our platform is applicable to a range of industries, including the pharmaceutical, food, chemical and energy sectors. Our main focus is on high value products in the healthcare, nutrition and personal care space.